ACCD
Accolade Inc. (acquired by Transcarent; no ACCD listing)
Is ACCD Halal?
Transcarent completed Accolade's acquisition in April 2025 and ACCD ceased public trading; the healthcare-navigation analysis remains qualitative without current standalone ratios.
What You Should Know
ACCD is a preserved Accolade route. Transcarent completed the merger on April 8, 2025, making Accolade private and ending Nasdaq trading. Health advocacy, benefits navigation, expert medical opinion and virtual-care services remain the qualitative subject, while data privacy, reimbursement and clinical oversight require review; no current standalone ACCD quantitative screen is applicable.
⚠️ Concerns
- •ACCD ceased public trading after Transcarent's acquisition
- •Healthcare data privacy and security
- •Care quality, reimbursement and clinical oversight
- •ACCD is a preserved Transcarent-acquisition alias; the URL is unchanged
Current quantitative Sharia screen
Based on issuer-status figures for the period ended 2025-04-08; calculated 2026-07-15.
- Financial
- Not calculated
- Overall
- Not calculated
Not calculated because ACCD became private and ceased public listing in April 2025.
- Financial
- Not calculated
- Overall
- Not calculated
No current standalone Accolade financial statement is available.
- Financial
- Not calculated
- Overall
- Not calculated
Not calculated for the delisted historical security.
- Financial
- Not calculated
- Overall
- Not calculated
ACCD has no current public-market price or market-cap series.
Business-activity disclosure
Accolade historically provided health advocacy, expert medical opinion, benefits navigation and virtual primary care. Healthcare services are generally permissible in principle, while customer data, clinical materials, reimbursement and care-delivery questions remain qualitative; ACCD is no longer publicly investable.
Limitation: No current standalone ACCD balance sheet, revenue statement or public-market price exists for a reproducible quantitative screen.
Purification
No current standalone ACCD issuer income is available for a purification calculation.
Inputs, assumptions and primary sources
- Transcarent completed the Accolade merger on April 8, 2025; Accolade became privately held and ACCD ceased to be listed on Nasdaq.
- No parent-company or private-company figures are substituted for a standalone ACCD screen, so numerical ratios are intentionally not calculated.
- The route and its healthcare-navigation, benefits, virtual-care and data-privacy qualitative analysis are preserved.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →